LENZ (lenzilumab) / Humanigen 
Welcome,         Profile    Billing    Logout  
 16 Diseases   3 Trials   3 Trials   683 News 


«1234567»
  • ||||||||||  lenzilumab (KB003) / Humanigen
    Look at lenzilumab (Twitter) -  Nov 24, 2020   
  • ||||||||||  LENZ (lenzilumab) / Humanigen
    Enrollment open:  ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19 (clinicaltrials.gov) -  Oct 22, 2020   
    P2,  N=200, Recruiting, 
    ZUMA-19 is open and actively recruiting pts. Not yet recruiting --> Recruiting
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, lenzilumab (KB003) / Humanigen
    Clinical, Journal:  Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019. (Pubmed Central) -  Oct 15, 2020   
    He was subsequently treated with tocilizumab with marked clinical improvement and a decrease in acute phase reactants within 48 h. Discussion &  This case demonstrates the effective use of tocilizumab in the treatment of COVID-19 and suggests the superiority of tocilizumab over lenzilumab in the management of this cytokine-mediated syndrome.
  • ||||||||||  Review, Journal:  Pharmaco-Immunomodulatory Therapy in COVID-19. (Pubmed Central) -  Sep 18, 2020   
    Non-specific immune modulators include human immunoglobulin, corticosteroids such as dexamethasone, interferons, statins, angiotensin pathway modulators, macrolides (e.g. azithromycin, clarithromycin), hydroxychloroquine and chloroquine, colchicine, and prostaglandin D2 modulators such as ramatroban...Research efforts should focus not only on the most relevant immunomodulatory strategies but also on the optimal timing of such interventions to maximize therapeutic outcomes. In this review, we discuss the potential role and safety of these agents in the management of severe COVID-19, and their impact on survival and clinical symptoms.
  • ||||||||||  Review, Journal:  Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies. (Pubmed Central) -  Aug 6, 2020   
    Anti-GM-CSF monoclonal antibodies, TJ003234 and gimsilumab, will be tested in clinical trials in patients with COVID-19, while lenzilumab received FDA approval for compassionate use. These trials will help inform whether blunting the inflammatory signaling provided by the GM-CSF axis in COVID-19 is beneficial.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, lopinavir/ritonavir / Generic mfg.
    Review, Journal:  Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof). (Pubmed Central) -  Jul 17, 2020   
    Clinically available and investigational immunomodulators, such as the interleukin 6 inhibitors tocilizumab and sarilumab and the anti-granulocyte-macrophage colony-stimulating factor lenzilumab, are being tested for their anticipated effect in counteracting the pro-inflammatory cytokine environment that characterizes severe and critical COVID-19...The authors, therefore, encourage the enrollment of eligible patients to multiple ongoing clinical trials that assess the efficacy and safety of these candidate therapies. Until the results of controlled trials are available, none of the suggested therapeutics is clinically proven as an effective therapy for COVID-19.
  • ||||||||||  LENZ (lenzilumab) / Humanigen
    Enrollment open:  Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19 (clinicaltrials.gov) -  May 3, 2020   
    P3,  N=238, Recruiting, 
    Until the results of controlled trials are available, none of the suggested therapeutics is clinically proven as an effective therapy for COVID-19. Not yet recruiting --> Recruiting
  • ||||||||||  LENZ (lenzilumab) / Humanigen
    Trial completion, Trial completion date, Trial primary completion date:  Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML) (clinicaltrials.gov) -  Feb 28, 2020   
    P1,  N=15, Completed, 
    Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial completion date: Oct 2019 --> Feb 2020 | Trial primary completion date: Oct 2019 --> Feb 2020
  • ||||||||||  LENZ (lenzilumab) / Humanigen
    Enrollment closed, Trial completion date, Trial primary completion date:  Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML) (clinicaltrials.gov) -  Aug 7, 2019   
    P1,  N=15, Active, not recruiting, 
    Phase II studies with lenzilumab in combination with CART19 therapy are planned. Recruiting --> Active, not recruiting | Trial completion date: Oct 2018 --> Oct 2019 | Trial primary completion date: Jul 2018 --> Oct 2019
  • ||||||||||  LENZ (lenzilumab) / Humanigen
    Enrollment status, Enrollment change, Trial initiation date, Trial primary completion date:  Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML) (clinicaltrials.gov) -  Jul 27, 2016   
    P1,  N=18, Recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Oct 2018 --> Oct 2019 | Trial primary completion date: Jul 2018 --> Oct 2019 Enrolling by invitation --> Recruiting | N=31 --> 18 | Initiation date: Nov 2015 --> Jul 2016 | Trial primary completion date: Oct 2017 --> Jul 2018